Stada Plans Multi-Billion Euro IPO in Autumn

German pharmaceutical company Stada is planning to revive its initial public offering (IPO) in the autumn, aiming for a multi-billion-euro listing in Frankfurt, contingent on favorable market conditions. The IPO, potentially valued around €10 billion, would mark Stada's return to the stock market after seven years of private ownership by Bain Capital and Cinven, providing these investors an exit opportunity and allowing the company to reduce its €5.7 billion debt. Stada's CEO, Peter Goldschmidt, highlighted the company's strong first-half performance with 6% revenue growth driven by specialty medicines and a record pipeline of 50 new in-licensing deals, noting that the firm's minimal exposure to the U.S. market is advantageous amid current geopolitical tensions. The company has restructured under a Dutch holding while maintaining its headquarters in Bad Vilbel, with Deutsche Bank advising on the transaction. Although initial IPO plans were postponed earlier this year due to market volatility linked to tariff threats under President Donald Trump's administration, stabilized market conditions and a new EU-US trade agreement have improved prospects. The IPO is expected to be one of Europe's largest this year and could lead to Stada's inclusion in Germany's MDAX index.